Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons

Poorvi Chordia, Rodger D. MacArthur

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Crofelemer is the first US FDA-approved drug for symptomatic relief in HIV-infected persons on antiretroviral therapy (ART) who have non-infectious diarrhea. With the availability of ART, there is increased survival and decrease in gastrointestinal opportunistic infections. However, diarrhea secondary to ART and HIV enteropathy is common in HIV-infected persons. Crofelemer is manufactured from the red latex sap of the Croton lechleri tree in South America. It has a unique mechanism leading to inhibition of chloride ion secretion by blocking chloride channels in the gastrointestinal lumen. This reduces efflux of sodium and water, which in turn reduces the frequency and consistency of diarrhea. Crofelemer is well tolerated due to minimal systemic absorption and has a good safety profile. The availability of crofelemer will likely have a positive impact on the quality of life in HIV-infected persons and also increase compliance to ART.

Original languageEnglish (US)
Pages (from-to)591-600
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Volume7
Issue number7
DOIs
StatePublished - Sep 2013

Fingerprint

Diarrhea
HIV
HIV Enteropathy
Croton
Chloride Channels
South America
Opportunistic Infections
Latex
Therapeutics
Chlorides
Sodium
Quality of Life
Ions
Safety
Survival
crofelemer
Water
Pharmaceutical Preparations

Keywords

  • Chloride channels
  • Crofelemer
  • HIV
  • Secretory diarrhea

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Medicine(all)

Cite this

Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons. / Chordia, Poorvi; MacArthur, Rodger D.

In: Expert Review of Gastroenterology and Hepatology, Vol. 7, No. 7, 09.2013, p. 591-600.

Research output: Contribution to journalReview article

@article{37cc0e51486846de95151d5ba4948de0,
title = "Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons",
abstract = "Crofelemer is the first US FDA-approved drug for symptomatic relief in HIV-infected persons on antiretroviral therapy (ART) who have non-infectious diarrhea. With the availability of ART, there is increased survival and decrease in gastrointestinal opportunistic infections. However, diarrhea secondary to ART and HIV enteropathy is common in HIV-infected persons. Crofelemer is manufactured from the red latex sap of the Croton lechleri tree in South America. It has a unique mechanism leading to inhibition of chloride ion secretion by blocking chloride channels in the gastrointestinal lumen. This reduces efflux of sodium and water, which in turn reduces the frequency and consistency of diarrhea. Crofelemer is well tolerated due to minimal systemic absorption and has a good safety profile. The availability of crofelemer will likely have a positive impact on the quality of life in HIV-infected persons and also increase compliance to ART.",
keywords = "Chloride channels, Crofelemer, HIV, Secretory diarrhea",
author = "Poorvi Chordia and MacArthur, {Rodger D.}",
year = "2013",
month = "9",
doi = "10.1586/17474124.2013.832493",
language = "English (US)",
volume = "7",
pages = "591--600",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons

AU - Chordia, Poorvi

AU - MacArthur, Rodger D.

PY - 2013/9

Y1 - 2013/9

N2 - Crofelemer is the first US FDA-approved drug for symptomatic relief in HIV-infected persons on antiretroviral therapy (ART) who have non-infectious diarrhea. With the availability of ART, there is increased survival and decrease in gastrointestinal opportunistic infections. However, diarrhea secondary to ART and HIV enteropathy is common in HIV-infected persons. Crofelemer is manufactured from the red latex sap of the Croton lechleri tree in South America. It has a unique mechanism leading to inhibition of chloride ion secretion by blocking chloride channels in the gastrointestinal lumen. This reduces efflux of sodium and water, which in turn reduces the frequency and consistency of diarrhea. Crofelemer is well tolerated due to minimal systemic absorption and has a good safety profile. The availability of crofelemer will likely have a positive impact on the quality of life in HIV-infected persons and also increase compliance to ART.

AB - Crofelemer is the first US FDA-approved drug for symptomatic relief in HIV-infected persons on antiretroviral therapy (ART) who have non-infectious diarrhea. With the availability of ART, there is increased survival and decrease in gastrointestinal opportunistic infections. However, diarrhea secondary to ART and HIV enteropathy is common in HIV-infected persons. Crofelemer is manufactured from the red latex sap of the Croton lechleri tree in South America. It has a unique mechanism leading to inhibition of chloride ion secretion by blocking chloride channels in the gastrointestinal lumen. This reduces efflux of sodium and water, which in turn reduces the frequency and consistency of diarrhea. Crofelemer is well tolerated due to minimal systemic absorption and has a good safety profile. The availability of crofelemer will likely have a positive impact on the quality of life in HIV-infected persons and also increase compliance to ART.

KW - Chloride channels

KW - Crofelemer

KW - HIV

KW - Secretory diarrhea

UR - http://www.scopus.com/inward/record.url?scp=84899778584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899778584&partnerID=8YFLogxK

U2 - 10.1586/17474124.2013.832493

DO - 10.1586/17474124.2013.832493

M3 - Review article

C2 - 24070150

AN - SCOPUS:84899778584

VL - 7

SP - 591

EP - 600

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 7

ER -